**Question:** Drug of choice for peptic ulcer disease caused by chronic use of NSAIDS:

*A. Omeprazole*
*B. Ibuprofen*
*C. Pantoprazole*
*D. Diclofenac*

**Core Concept:**
Peptic ulcer disease (PUD) is a condition characterized by the formation of ulcers in the lining of the stomach or the duodenum. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) is a major risk factor for the development of PUD due to their ability to inhibit cyclooxygenase (COX) enzymes, which lead to reduced production of prostaglandins, decreased mucus production, and impaired gastric mucosal blood flow.

**Why the Correct Answer is Right:**
Omeprazole is a proton pump inhibitor (PPI) that works by irreversibly inhibiting the H+/K+-ATPase enzyme, which is responsible for gastric acid secretion. By reducing gastric acid secretion, omeprazole effectively protects the gastric mucosa from the harmful effects of NSAIDs, thus reducing the risk of developing peptic ulcers.

**Why Each Wrong Option is Incorrect:**
Both Ibuprofen and Diclofenac are NSAIDs that share the same mechanism of action as Diclofenac, which is a nonselective COX inhibitor. Chronic use of these drugs can lead to mucosal damage and increased risk of PUD.

C. Pantoprazole is also a PPI, but it is not the optimal choice among the options provided. While effective in reducing gastric acid secretion, other drugs like Omeprazole and Rabeprazole may have better efficacy and safety profiles in the context of NSAID-induced PUD.

**Clinical Pearl:**
When treating patients with chronic use of NSAIDs, it is essential to consider the use of a PPI like Omeprazole to protect the gastric mucosa from NSAID-induced damage. However, patient-specific factors such as comorbidities, drug interactions, and individual response should be taken into account when selecting the most appropriate medication for gastric protection. In some cases, a PPI like Pantoprazole, Rabeprazole, or Esomeprazole may be a more suitable choice based on patient-specific factors.